Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates

Company Performance - Vanda Pharmaceuticals reported a quarterly loss of $0.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, and compared to a loss of $0.09 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $56.26 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.24%, but showing an increase from $47.65 million in the same quarter last year [2] - Over the last four quarters, Vanda has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Vanda shares have increased by approximately 16.5% since the beginning of the year, slightly underperforming the S&P 500's gain of 17.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.20 on revenues of $64 million, and for the current fiscal year, it is -$1.75 on revenues of $226.63 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Vanda belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]